Subsidiaries and Affiliates
SCILEX Pharmaceuticals, located in San Diego, California, a majority-owned subsidiary of Sorrento Therapeutics, dedicated to the final stage development and commercialization of products issued from the pain management development activities. The Company’s lead product under development, ZTlido™ (lidocaine patch 1.8%), is a branded lidocaine patch formulation for the treatment of relieving the pain of post-herpetic neuralgia, also referred to as after-shingles pain.
Bioserv, located in San Diego, California is a fully owned subsidiary of Sorrento Therapeutics. Founded in 1988, the organization is a leading boutique contract manufacturing service provider with over 35,000 square feet of facilities whose core competencies are centered in aseptic and non-aseptic bulk formulation; filtration; filling; stoppering; lyophilization services; labeling; finished goods assembly; kitting and packaging; as well as controlled temperature storage and distribution services to support Pre-Clinical, Phase I and II Clinical Trial drug products, medical device reagents, medical diagnostic reagents and kits, and life science reagents.
In September 2015, LA CELL was established as a joint venture between Sorrento and the City of Hope Comprehensive National Cancer Center. LA CELL has exclusively licensed City of Hope’s unprecedented innovative technology, and then developed it into a best-in-class intracellular targeting antibody (iTAbs) platform in conjunction with Sorrento’s fully human G-MAB™ library and proprietary conjugation chemistry. Currently, anti-STAT3 and KRASG12D iTAbs are our lead programs in preclinical development for the treatment of various cancers. As a pure play, intracellular targeting antibody platform, LA CELL combines the specificity (targeting power), stability and safety of antibodies with the intracellular accessibility of small molecules for a large druggable target space opportunity. The advent of LA CELL iTAbs technology enables the development of new strategies leveraged to pursue molecular targets previously considered to be undruggable. LA CELL is open to working with biopharmaceutical and biotechnology industry partners to leverage the technology for areas beyond cancer therapy.
In 2008, Concortis Biosystems was established with the goal to better serve the scientific and pharmaceutical community with high quality antibody-drug conjugate (ADC) reagents and services. In 2013, Sorrento acquired Concortis creating a top tier ADC company. The combination of G-MAB™ (fully human antibody library) with Concortis proprietary toxins, linkers, and conjugation methods has the potential to generate industry-leading, 3rd generation ADCs.
Concortis is currently exploring over 20 different ADC options (pre-clinical) with applications in oncology and beyond. On October 19, 2015, Sorrento announced the creation of Levena Biopharma as an independent entity to offer the market a broad range of ADC services from the initiation of an ADC project through cGMP manufacturing of ADCs to phase I/II clinical studies. For detail information, please visit www.levenabiopharma.com
TNK is a majority-owned subsidiary of Sorrento. TNK is focused on the development and commercialization of cellular therapies to address unmet medical needs in oncology. TNK technologies harness the adaptive and innate immune system by reprogramming immune cells to recognize and efficiently kill cancer cells. For these cellular immunotherapies, TNK’s utilizes immune cells, including T cells and Natural Killer, or “NK”, cells.
Virttu is the most recent TNK acquisition, as part of the TNK family of cellular technologies. The lead oncolytic product Seprehvir® has been administered to 100 patients age ranging from 8 to 84 years with many types of cancer including brain, melanoma, head and neck cancer, sarcomas, neuroblastoma and mesothelioma (a devastating lung cancer associated with asbestos exposure). In these patients, Seprehvir can be administered by the route most suitable for their disease which includes systemic administration by intravenous infusion, direct intra-tumor injection, and loco-regional infusion.
Ark Animal Health is a wholly owned subsidiary of Sorrento. Ark was formed in 2014 to bring to the companion animal market innovative solutions issued from Sorrento’s human research and development activities. It is being organized to become a fully independent and self-sufficient organization once it reaches commercial stage (products ready to receive FDA approval).
Ark’s lead development program (ARK-001) is a single dose resiniferatoxin (RTX) sterile injectable solution. ARK-001 has received FDA CVM (Center for Veterinary Medicine) MUMS (minor use/minor species) designation for the control of bone cancer pain in dogs. Conditional approval is expected by late 2018. Other projects include additional indications for RTX in areas such as chronic articular pain in companion animals, neuropathic pain in horses, and idiopathic cystitis in cats, as well as exploring development opportunities in the area of infectious diseases or cancer treatment.